XCT 790 is a pharmacological aggrephagy inducer in a yeast model of proteotoxicity

We tested whether XCT 790 treatment results in aggregate clearance. In yeast cells overexpressing α‐synuclein‐EGFP, XCT 790 treatment led to vacuolar degradation of α‐synuclein‐EGFP with the restoration of normal plasma membrane localization of α‐synuclein‐EGFP as seen by others. We employed an α‐synuclein‐EGFP aggregate degradation assay in yeast. XCT 790 treatment significantly cleared α‐synuclein‐EGFP in the WT strain (~2.5‐fold, untreated vs. XCT 790 treated, p < .001)